louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06113822: Investigation of the Effect of Body Mass Index and Anxiety on Masseter Muscle Thickness on Ultrasonography
Official title: Investigation of The Effect of Body Mass Index and Anxiety on Masseter Muscle Thickness on Ultrasonography
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anxiety
Keywords: anxiety
body mass index
masseter muscle
obesity
ultrasonography
Lead sponsor: Firat University
Sponsor class: OTHER
First posted: 2023-11-02
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals in the Turkish population aged 18-45

Brief summary: The aim of this study is to determine the effect of body mass index (BMI) and anxiety on masseter muscle thickness by using ultrasonography.

Detailed description: The aim of this study is to determine the effect of body mass index (BMI) and anxiety on masseter muscle thickness by using ultrasonography.

A total of 68 patients were included in this study. Height and weight of the patients were measured. BMI was calculated. The Control Group Without Anxiety - Normal BMI (15 patients) was composed of patients in general. Working groups were formed as High BMI \& Anxiety Normal (19 patients), Normal BMI \& High Anxiety (15 patients), and High BMI \& High Anxiety (19 patients). The Hospital Anxiety Depression Scale (HADS) was applied to the participants. Muscle thickness measurements were first measured by using the high-frequency linear scanning probe of an ultrasound device to measure the contraction and relaxation of the right masseter muscle. Then, the contraction and relaxation of the left masseter muscle was measured.

Eligibility criteria: Inclusion Criteria:

* The study group consisted of individuals between the ages of 18 and 45 who, according to an examination of the masseter muscles under the 'Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD),' had the presence of pain in at least one region in the palpation made from three regions (origin, center, attachment zone) or had pain in chewing muscles in the preceding month.

Exclusion Criteria:

* Exluded from the study where those who had experienced any systemic discomfort from the study group, those who had undergone acute temporomandibular joint trauma, those who had experienced early occlusion of the teeth, those who were using any moving dental prosthesis, those with clenching habits, those who use cigarette-alcohol, those with temporomandibular joint discomfort, and those with unilateral chewing habits.

Primary outcomes:
measure: BMI and anxiety
timeFrame: 2022
Secondary outcomes:
Other outcomes:
Locations:
city: Elazıg
country: Turkey
facility: Firat University
state: Elazığ
Study officials:
References:
Clinical trial NCT03452722: Neuroinflammatory Response in Patients With ICH and IVH Treated With rtPA
Official title: Neuroinflammatory Response in Patients With ICH and IVH Treated With rtPA
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertensive Intracerebral Hemorrhage
Intraventricular Hemorrhage
Brain Injuries
Keywords: secondary brain injury
neuroinflammation
Lead sponsor: University of Rijeka
Sponsor class: OTHER
First posted: 2018-03-02
Enrollment: 88
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All subjects from 18 to 80 years.

Brief summary: This study compares the neuroinflammatory response in patients with hypertensive ICH associated with IVH treated with intraventriculary applied rtPA, and the control group. The inflammatory mediator concentration is analyzed in local cerebrospinal liquor.


Eligibility criteria: Inclusion Criteria:

* Subjects with primary ICH with IVH
* ICH score 2-4, , with origin of the hematoma in the basal ganglia and blood in the third and/or ventricle
* Patient is not considered a surgical candidate by neurosurgery service

Exclusion Criteria:

* No history of diseases or drugs that affect the immunological system.
* ICH score 1 and 5
* Current participation in another research drug treatment protocol
* Previously known intracranial arteriovenous malformation or aneurysms
* Intracerebral hematoma considered to be related to trauma
* ICH is located in the pons
* Blood in the subarachnoid space visualized on CT scan

Primary outcomes:
measure: Cytokine concentration difference between two groups
timeFrame: Samples taken on day 0, day 1, day 3 and day 7.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Rijeka
name: Vlatka Sotosek Tokmadzic, PhD
role: STUDY_DIRECTOR
References:
citation: Hanley DF, Lane K, McBee N, Ziai W, Tuhrim S, Lees KR, Dawson J, Gandhi D, Ullman N, Mould WA, Mayo SW, Mendelow AD, Gregson B, Butcher K, Vespa P, Wright DW, Kase CS, Carhuapoma JR, Keyl PM, Diener-West M, Muschelli J, Betz JF, Thompson CB, Sugar EA, Yenokyan G, Janis S, John S, Harnof S, Lopez GA, Aldrich EF, Harrigan MR, Ansari S, Jallo J, Caron JL, LeDoux D, Adeoye O, Zuccarello M, Adams HP Jr, Rosenblum M, Thompson RE, Awad IA; CLEAR III Investigators. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet. 2017 Feb 11;389(10069):603-611. doi: 10.1016/S0140-6736(16)32410-2. Epub 2017 Jan 10.
citation: Dunatov S, Antoncic I, Bralic M, Jurjevic A. Intraventricular thrombolysis with rt-PA in patients with intraventricular hemorrhage. Acta Neurol Scand. 2011 Nov;124(5):343-8. doi: 10.1111/j.1600-0404.2010.01481.x. Epub 2011 Feb 8.
Clinical trial NCT01628822: Efficacy Study of Relaxation to 12 Weeks Against Placebo in the Overall Care Chronic Pain in Patients With Fibromyalgia
Official title: Pilot Study, Prospective, Single Center,Randomized, Single Blind, Evaluating the Efficacy of Relaxation to 12 Weeks Against Placebo, in the Overall Care Chronic Pain in Patients With Fibromyalgia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Fibromyalgia
Keywords: Fibromyalgia
Relaxation
Improving the quality of life
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2012-06-27
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective of this protocol is to measure the improvement of the overall situation of patients with diffuse chronic pain or fibromyalgia to 12 weeks by non-drug treatment relaxation.

Secondarily,is to evaluate the evolution of physical variables, psychological and social improvement of the quality of life. To evaluate the evolution of drug consumption


Eligibility criteria: Inclusion Criteria:

* Men or women over 18 years
* established diagnosis of fibromyalgia as defined by the American College of Rheumatology: widespread pain and eleven tender points at 18 sites listed (ACR, 1990)
* EVA ≥ 4 (on a scale of 10 cm)
* no change in treatment for 15 days, except for treatment "on demand" or "rescue"
* patient has given its written consent
* patient wishing to benefit from relaxation sessions
* people who can meet the self-assessment and hetero-assessment
* people with a social security number

Exclusion Criteria:

* any painful situation that cannot be distinguished from fibromyalgia pain by the patient
* patients untreated or treated for less than a month
* patient with psychosis or severe depression or severe anxiety or impulsivity characterized, at the discretion of the clinician.
* patients receiving benzodiazepines at the request
* patient with deafness
* patient after a body treatment using a relaxation method, relaxation therapy or hypnosis

Primary outcomes:
measure: scores on Fibromyalgia Impact Questionnaire (FIQ)
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: Activity Centre "Pain"
Study officials:
affiliation: Activity Centre "Pain", University Hospital of Amiens
name: SERRA Eric, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05391022: Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
Official title: A Phase 1, 2-Part Study to Evaluate the Effect of Food on Pharmacokinetics of Pelabresib (CPI-0610) and the Effect of Pelabresib on QTc in Patients With Advanced Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Malignancies
Solid Tumor
Hematological Malignancy
Keywords: Pelabresib
CPI 0610
Lead sponsor: Constellation Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2022-05-25
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Confirmed diagnosis of an advanced malignancy for which no effective standard treatment options are available
* Eastern Cooperative Oncology Group (ECOG) performance status of ≤2

Exclusion Criteria:

* Chronic or active conditions and/or concomitant medication use that would prohibit treatment

Primary outcomes:
measure: Run-In Food Effect Period: Area under the concentration time curve (AUC) based on pelabresib concentrations in plasma measured using validated plasma assay
timeFrame: 21 days
measure: Run-In Food Effect Period: maximal plasma concentration (Cmax) based on pelabresib concentrations in plasma measured using validated plasma assay
timeFrame: 21 days
measure: Run-In Food Effect Period: Time to maximal plasma concentration (Tmax) based on pelabresib concentrations in plasma measured using validated plasma assay
timeFrame: 21 days
measure: Continuous Treatment Period: Changes in QT and QTc intervals
timeFrame: 12 months
Secondary outcomes:
measure: -In Food Effect Period: Total amount (Ae[∞]) and fraction of dose (fe) of pelabresib
timeFrame: 24 hours
measure: Run-In Food Effect Period and Continuous Treatment Period: incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs)
timeFrame: 12 months
Other outcomes:
Locations:
city: Canton
country: United States
facility: Gabrail Cancer Center Research
state: Ohio
city: Gettysburg
country: United States
facility: Gettysburg Cancer Center
state: Pennsylvania
city: West Valley City
country: United States
facility: Start Mountain Region
state: Utah
city: Batumi
country: Georgia
facility: Hight Technology Hospital Medcenter
city: Tbilisi
country: Georgia
facility: K. Eristavi National Center of Experimental and Clinical Surgery
city: Tbilisi
country: Georgia
facility: Simon Khechinashvili University Hospital
city: Barcelona
country: Spain
facility: Barcelona HM Nou Delfos
city: Madrid
country: Spain
facility: Madrid - FJD
city: Madrid
country: Spain
facility: START CIOCC Hospital HM Sanchinarro
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocío
Study officials:
References:
Clinical trial NCT03812822: Describing the Effects of Insoles in Children With Increased Femoral Anteversion and Pes Planovalgus
Official title: The Effects of Using Insoles on Walking in Children With Increased Femoral Anteversion and Pes Planovalgus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Femoral Anteversion
Pes Planovalgus
Flat Foot
Keywords: Femoral anteversion, flat foot, insole, gait
Lead sponsor: Istanbul Kültür University
Sponsor class: OTHER
First posted: 2019-01-23
Enrollment: 21
Sex: ALL
Minimum age (years): 8
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: Increased Femoral Anteversion is a transverse plan problem that affects lower body alignment, walking and standing characteristics and also pes planovalgus mostly accompanies with IFA. It is shown that children with IFA and PPV have back and leg pain, fatigue, muscle cramps and they are under the risk for chronic disorders such as osteoarthritis, scoliosis and muscle injuries.

Insoles, which reduce pronation of foot (flat foot), provide apparently a static correction by supporting proper alignment in children with IFA and PPV. However, the dynamic effects of insoles to lower extremity biomechanics while walking is not known.

The aims of this study are to determine the effects of the insoles on walking biomechanics in children with IFA and PPV by comparing with their healthy peers.


Eligibility criteria: Inclusion Criteria:

* Insole Group Between the ages 7-15, Trochanteric Prominens Angle Test \> 20⁰, Hip internal rotation angle \> 60⁰, Without insole Foot Posture Index score \> 5, With insole Foot Posture Index score \> 4, Using their insoles' at least one month.
* Control Group Between the ages 7-15, Trochanteric Prominens Angle Test \< 20⁰, Foot Posture Index score \< 5, Without any neurologic or orthopedic disease

Exclusion Criteria:

Neurological and / or musculoskeletal problems, Orthopedic problems to prevent walking.

Primary outcomes:
measure: Gait Analysis
timeFrame: Day 1
measure: Static Foot Posture Assesment
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: İstanbul Kültür Üniversitesi
city: Istanbul
country: Turkey
facility: İstanbul University, Faculty of Medicine
Study officials:
affiliation: İstanbul Kültür University
name: Halenur Evrendilek, GRAD ASST
role: STUDY_CHAIR
affiliation: İstanbul Kültür University
name: Ekin Akalan, PROF
role: STUDY_DIRECTOR
affiliation: İstanbul Medipol University
name: Miray Budak, ASST PROF
role: STUDY_DIRECTOR
References:
Clinical trial NCT03681522: A Study on the Pain Control Effect of the Anesthetic Method During Prostate Biopsy: Comparison Between Pelvic Plexus Block and Periprosthetic Nerve Block
Official title: What is the Most Effective Local Anesthesia for Prostate-stained Ultrasonography-guided Biopsy in PPB and PNB?: A Single Center, Prospective, Randomized, Double Arm Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Transrectal Systematic Prostate Biopsy Related Pain
Keywords: local anesthesia
prostate, biopsy
transrectal
Lead sponsor: Gangnam Severance Hospital
Sponsor class: OTHER
First posted: 2018-09-24
Enrollment: 58
Sex: MALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study assesses differences in the effects of pelvic plexus block and periprostatic nerve block among various anesthetic methods that reduce the pain caused by prostate biopsy.

Detailed description: Recently, various types of local anesthetic methods have been attempted to reduce biopsy-related pain leading to changes in the type of anesthetic agents and site of injection. Of these anesthetics and combinations, pelvic plexus block and periprostatic nerve block seem to be the very effective way to control prostate biopsy-related pain. However, few studies have compared these two methods.

Eligibility criteria: Inclusion Criteria:

* abnormal prostate finding on digital rectal examination
* serum PSA level of \> 2.5 ng/mL
* Transrectal ultrasonographic abnormal lesion

Exclusion Criteria:

* under 50 years old
* a history of previous TRUS-guided biopsy
* chronic prostatitis/pelvic pain
* neurological conditions (dementia, Parkinson disease, or cerebral infarction)
* bleeding diathesis
* active UTI
* hemorrhoids/anal fissure/anal fistula
* known allergy to lidocaine

Primary outcomes:
measure: Visual analog scale-1
timeFrame: day 7~14
measure: Visual analog scale-2
timeFrame: day 7~14
measure: Visual analog scale-3
timeFrame: day 7~14
measure: Visual analog scale-4
timeFrame: day 7~14
Secondary outcomes:
measure: Rate of Complication
timeFrame: day 14~28
measure: Procedure time
timeFrame: day 7~14
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei University Medical College Gangnam Severance Hospital
Study officials:
References:
Clinical trial NCT00258622: NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain
Official title: NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain: a Randomized, Double-Blind, Placebo-Controlled, Crossover Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pain
Keywords: Peripheral neuropathic pain
Neuropathic pain
Chronic pain
Lead sponsor: Danish Pain Research Center
Sponsor class: OTHER
Collaborators: name: NeuroSearch A/S
First posted: 2005-11-28
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Purpose: To evaluate the efficacy, tolerability and safety of NS1209 compared to lidocaine and placebo in patients with peripheral chronic neuropathic pain.


Eligibility criteria: Inclusion Criteria:

* Age \>18 years
* Neuropathic pain and allodynia after a peripheral nerve injury (VAS \>= 4)

Exclusion Criteria:

* Patients who cannot cooperate and do no understand Danish
* Fertile women
* Clinically significant abnormality or disease
* Drug and alcohol abuse
* Clinically abnormal ECG
* Hypersensitivity to any of the treatments
* Patients in treatment with cimetedin, antidepressants, antipsychotics, antiepileptics except gabapentin, anticoagulants, Na channel blockers and beta blockers
* Patients who have previously been treated in a NS1209 study
* Patients treated with an investigational drug

Primary outcomes:
measure: - Spontaneous ongoing pain intensity (VAS 0-100)
Secondary outcomes:
measure: Number of responders (at least 33% pain reduction)
measure: Effect on evoked allodynia (VAS 0-100)
measure: Pain relief for overall spontaneous pain (complete, good, moderate, slight, none or worse)
measure: Feeling of unpleasantness (VAS 0-100)
measure: Pain on movements (VAS 0-100)
measure: Daily pain (NSP 0-10)
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Danish Pain Research Center, Aarhus University Hospital
Study officials:
affiliation: Danish Pain Research Center, Aarhus University Hospital
name: Troels S Jensen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05444322: A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Official title: A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Mantle Cell Lymphoma
Diffuse Large B-cell Lymphoma
Follicular Lymphoma
Lead sponsor: Zhejiang University
Sponsor class: OTHER
First posted: 2022-07-05
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is designed to explore the safety and tolerability of RD14-01 for patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma. And to evaluate the efficacy and pharmacokinetics of RD14-01 in patients.


Eligibility criteria: Inclusion Criteria:

1. Aged 18 to 75 years.
2. Diagnosis of r/r MCL, DLBCL, or FL (Grade 1, 2 and 3a).
3. ECOG: 0-1.
4. Life expectancy greater than 3 months.
5. Cardiac left ventricle ejection fraction ≥50%.
6. Informed consent explained to, understood by and signed by the patient/guardian. Patient/guardian is given a copy of informed consent.

Exclusion Criteria:

1. Pregnant or lactating.
2. Hepatitis B surface antigen (HBsAg) or hepatitis B e-antigen (HBeAg) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection is not within the normal range; hepatitis C virus (HCV) antibody positive; human immunodeficiency virus (HIV) antibody positive; syphilis antibody positive; cytomegalovirus (CMV) DNA positive; Epstein-Barr virus (EBV) DNA positive.
3. Central nervous system (CNS) metastases.
4. Participated in other clinical studies within 4 weeks prior to screening.
5. History of alcoholism, drug abuse or mental illness.
6. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.

Primary outcomes:
measure: Dose-limiting toxicity
timeFrame: Up to 2 years
measure: Maximum tolerable dose
timeFrame: Up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: The First Affiliated Hospital, College of Medicine, Zhejiang University
state: Zhejiang
Study officials:
References:
Clinical trial NCT03179722: Studying the Impact of a Medication Use Evaluation by the Community Pharmacist
Official title: Studying the Impact of a Medication Use Evaluation by the Community Pharmacist
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aging
Keywords: Aging
Drug-related problems
Medication review
Community pharmacist
Medication use
Lead sponsor: KU Leuven
Sponsor class: OTHER
Collaborators: name: Association of Belgian Pharmacies (APB)
First posted: 2017-06-07
Enrollment: 453
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel group intervention study. In a subset of 140 patients, a pre-post study design is used.
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: In this intervention study, 75 Belgian community pharmacies each recruit 12 patients for an intermediate medication review. For each patient, the identified drug-related problems and subsequent interventions are registered using the PharmDisc classification. In a subset of Dutch speaking patients, a pretest-posttest single group design is used to measure the impact of this review on patient related outcomes using questionnaires. The primary outcome is the medication related quality of life, measured via the living with medicines questionnaire. Other patient reported outcomes include adherence, self-management, patient satisfaction, fall incidents and use of emergency healthcare services. Medication records are also collected to objectively measure adherence before and after the intervention.


Eligibility criteria: Inclusion Criteria:

* Patients should be 70 years or older
* Use five or more drugs on a regular basis (prescription or non-prescription drugs)
* Live in the ambulatory setting
* Obtain his medication from this pharmacy on a regular basis

Exclusion Criteria:

-

Primary outcomes:
measure: Drug-related problems & interventions
timeFrame: One timeframe: during the medication review
measure: Change in medication related quality of life
timeFrame: Three timepoints: Before the review, during review (week 3), after the review (week 12)
Secondary outcomes:
measure: Change in adherence
timeFrame: 9 months before and after the intervention
measure: Change in adherence
timeFrame: Two timepoints: Before the review, after the review (week 12)
measure: Change in self-management
timeFrame: Two timepoints: Before the review, after the review (week 12)
measure: Change in use of emergency healthcare services & fall incidents
timeFrame: Two timepoints: Before the review, after the review (week 12)
measure: Satisfaction with the new service
timeFrame: One timepoint: during the review (week 3)
Other outcomes:
Locations:
Study officials:
References:
citation: Wuyts J, Maesschalck J, De Wulf I, Foubert K, Boussery K, De Lepeleire J, Foulon V. Studying the impact of a medication use evaluation for polymedicated older patients by the community pharmacist (SIMENON): study protocol. BMC Health Serv Res. 2018 Aug 8;18(1):623. doi: 10.1186/s12913-018-3440-z.